S&P ASX All Technology

US Dollar vs AUD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

CYTO Altamira Therapeutics Ltd

1.5802

-0.0398 (-2.46%)

03 May 2024 - Closed

Delayed by 15 minutes

Form EFFECT - Notice of Effectiveness

Altamira Therapeutics (NASDAQ:CYTO)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more Altamira Therapeutics Charts.

Altamira Therapeutics (NASDAQ:CYTO)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more Altamira Therapeutics Charts.

Altamira Therapeutics Ltd News

Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation
Wednesday 1 May 2024 (2 days ago) • GlobeNewswire Inc.

Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal
Wednesday 24 April 2024 (1 week ago) • GlobeNewswire Inc.

Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results
Wednesday 10 April 2024 (3 weeks ago) • GlobeNewswire Inc.

Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024
Thursday 4 April 2024 (4 weeks ago) • GlobeNewswire Inc.

Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines
Monday 25 March 2024 (1 month ago) • GlobeNewswire Inc.

Altamira Therapeutics’ Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed Journal
Thursday 8 February 2024 (3 months ago) • GlobeNewswire Inc.

Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment
Thursday 25 January 2024 (3 months ago) • GlobeNewswire Inc.

Form 424B4 - Prospectus [Rule 424(b)(4)]
Tuesday 23 January 2024 (3 months ago) • Edgar (US Regulatory)

Form EFFECT - Notice of Effectiveness
Monday 22 January 2024 (3 months ago) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Saturday 20 January 2024 (3 months ago) • Edgar (US Regulatory)

Form 424B5 - Prospectus [Rule 424(b)(5)]
Saturday 20 January 2024 (3 months ago) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Saturday 20 January 2024 (3 months ago) • Edgar (US Regulatory)

More Altamira Therapeutics Ltd News Articles

National Australia Bank

Australian SE All Ordina...

Australia And New Zealan...

JP Morgan Chase

Gold vs US Dollar

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions